Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies

Amelia Licari, Riccardo Castagnoli, Elisabetta De Sando, Gian Luigi Marseglia

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Given the multifaceted effector functions of IgE in immediate hypersensitivity, late-phase reactions, regulation of IgE receptor expression and immune modulation, IgE antibodies have long represented an attractive target for therapeutic agents in asthma and other allergic diseases. Effective pharmacologic blockade of the binding of IgE to its receptors has become one of most innovative therapeutic strategies in the field of allergic diseases in the last 10 years. Areas covered: The latest strategies targeting IgE include the development of a therapeutic vaccine, able to trigger our own immune systems to produce therapeutic anti-IgE antibodies, potentially providing a further step forward in the treatment of allergic diseases. The aim of this review is to discuss the discovery strategy, preclinical and early clinical development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. Expert opinion: Outside the area of development of humanized anti-IgE monoclonal antibodies, the research field of therapeutic IgE-targeted vaccines holds potential benefits for the treatment of allergic diseases. However, most of the experimental observations in animal models have not yet been translated into new treatments and evidence of human efficacy and safety of this new therapeutic strategy are still lacking.

Original languageEnglish
Pages (from-to)429-434
Number of pages6
JournalExpert Opinion on Biological Therapy
Volume17
Issue number4
DOIs
Publication statusPublished - Apr 3 2017

Fingerprint

Conjugate Vaccines
Subunit Vaccines
Immunoglobulin E
Peptides
Vaccines
Therapeutics
IgE Receptors
Immune system
Therapeutic Human Experimentation
Immediate Hypersensitivity
Expert Testimony
Animals
Monoclonal Antibodies
Modulation
anti-IgE antibodies
Immune System
Asthma
Animal Models
Antibodies
Safety

Keywords

  • adjuvants
  • allergy
  • anti-IgE
  • asthma
  • IgE
  • omalizumab
  • vaccine
  • virus-like particles

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. / Licari, Amelia; Castagnoli, Riccardo; De Sando, Elisabetta; Marseglia, Gian Luigi.

In: Expert Opinion on Biological Therapy, Vol. 17, No. 4, 03.04.2017, p. 429-434.

Research output: Contribution to journalReview article

@article{9667745aa6d64d87962ae33b0d95962d,
title = "Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies",
abstract = "Introduction: Given the multifaceted effector functions of IgE in immediate hypersensitivity, late-phase reactions, regulation of IgE receptor expression and immune modulation, IgE antibodies have long represented an attractive target for therapeutic agents in asthma and other allergic diseases. Effective pharmacologic blockade of the binding of IgE to its receptors has become one of most innovative therapeutic strategies in the field of allergic diseases in the last 10 years. Areas covered: The latest strategies targeting IgE include the development of a therapeutic vaccine, able to trigger our own immune systems to produce therapeutic anti-IgE antibodies, potentially providing a further step forward in the treatment of allergic diseases. The aim of this review is to discuss the discovery strategy, preclinical and early clinical development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. Expert opinion: Outside the area of development of humanized anti-IgE monoclonal antibodies, the research field of therapeutic IgE-targeted vaccines holds potential benefits for the treatment of allergic diseases. However, most of the experimental observations in animal models have not yet been translated into new treatments and evidence of human efficacy and safety of this new therapeutic strategy are still lacking.",
keywords = "adjuvants, allergy, anti-IgE, asthma, IgE, omalizumab, vaccine, virus-like particles",
author = "Amelia Licari and Riccardo Castagnoli and {De Sando}, Elisabetta and Marseglia, {Gian Luigi}",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/14712598.2017.1289172",
language = "English",
volume = "17",
pages = "429--434",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies

AU - Licari, Amelia

AU - Castagnoli, Riccardo

AU - De Sando, Elisabetta

AU - Marseglia, Gian Luigi

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: Given the multifaceted effector functions of IgE in immediate hypersensitivity, late-phase reactions, regulation of IgE receptor expression and immune modulation, IgE antibodies have long represented an attractive target for therapeutic agents in asthma and other allergic diseases. Effective pharmacologic blockade of the binding of IgE to its receptors has become one of most innovative therapeutic strategies in the field of allergic diseases in the last 10 years. Areas covered: The latest strategies targeting IgE include the development of a therapeutic vaccine, able to trigger our own immune systems to produce therapeutic anti-IgE antibodies, potentially providing a further step forward in the treatment of allergic diseases. The aim of this review is to discuss the discovery strategy, preclinical and early clinical development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. Expert opinion: Outside the area of development of humanized anti-IgE monoclonal antibodies, the research field of therapeutic IgE-targeted vaccines holds potential benefits for the treatment of allergic diseases. However, most of the experimental observations in animal models have not yet been translated into new treatments and evidence of human efficacy and safety of this new therapeutic strategy are still lacking.

AB - Introduction: Given the multifaceted effector functions of IgE in immediate hypersensitivity, late-phase reactions, regulation of IgE receptor expression and immune modulation, IgE antibodies have long represented an attractive target for therapeutic agents in asthma and other allergic diseases. Effective pharmacologic blockade of the binding of IgE to its receptors has become one of most innovative therapeutic strategies in the field of allergic diseases in the last 10 years. Areas covered: The latest strategies targeting IgE include the development of a therapeutic vaccine, able to trigger our own immune systems to produce therapeutic anti-IgE antibodies, potentially providing a further step forward in the treatment of allergic diseases. The aim of this review is to discuss the discovery strategy, preclinical and early clinical development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. Expert opinion: Outside the area of development of humanized anti-IgE monoclonal antibodies, the research field of therapeutic IgE-targeted vaccines holds potential benefits for the treatment of allergic diseases. However, most of the experimental observations in animal models have not yet been translated into new treatments and evidence of human efficacy and safety of this new therapeutic strategy are still lacking.

KW - adjuvants

KW - allergy

KW - anti-IgE

KW - asthma

KW - IgE

KW - omalizumab

KW - vaccine

KW - virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=85014813895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014813895&partnerID=8YFLogxK

U2 - 10.1080/14712598.2017.1289172

DO - 10.1080/14712598.2017.1289172

M3 - Review article

C2 - 28132528

AN - SCOPUS:85014813895

VL - 17

SP - 429

EP - 434

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 4

ER -